BioNTech SE (BNTX)
$119.34 $2.08 (1.78%) 4:38 PM 12/11/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$29.18B -
Day's Range
$118.64 - $121.88 -
Volume
798,953 -
52 Week Low / High
$76.53 - $131.49 -
PE Ratio
- -
PEG Ratio
0.04 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 10
- Strong Buy
- 5
- Buy
- 4
- Hold
- 0
- Sell
- 0
- Strong Sell
- $151.10
- Target Price
Company News
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment — Oct 21st, 2024
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on its Phase 3 PRESERVE-003 trial. The open-label, r...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024 — Oct 21st, 2024
BioNTech SE MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast t...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024 — Oct 21st, 2024
BioNTech SE MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast t...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024 — Oct 21st, 2024
BioNTech SE MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast t...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment — Oct 21st, 2024
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on its Phase 3 PRESERVE-003 trial. The open-label, r...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024 — Oct 21st, 2024
BioNTech SE MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast t...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment — Oct 21st, 2024
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on its Phase 3 PRESERVE-003 trial. The open-label, r...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment — Oct 21st, 2024
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on its Phase 3 PRESERVE-003 trial. The open-label, r...
-
BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It. — Nov 19th, 2024
BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity. Evercore ISI analyst Cory Kasimov upgraded the German drugmaker’s stock to Outperform from In Lin...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat — Nov 4th, 2024
BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates. Continue reading View comments...
-
Vaccine Stocks Drop on Worries About an RFK Jr. Role — Nov 6th, 2024
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants”...
Portfolio
Comprised of 1 portfolios